KPTI supply chain intelligence for Karyopharm Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Karyopharm Therapeutics Inc. (KPTI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| THIRD-PARTY-CONTRACT-MANUFACTURERS | THIRD-PARTY-CONTRACT-MANUFACTURERS | 92% | We currently rely, and expect to continue to rely, on third-party contract manufacturers to manufacture our products and product candidates for our commercial and clinical use. |
| ADVERTISING-AGENCIES | ADVERTISING-AGENCIES | 90% | We employ third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support-related services, to assist with our commercial activities. |
| MARKET-RESEARCH-FIRMS | MARKET-RESEARCH-FIRMS | 90% | We employ third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support-related services, to assist with our commercial activities. |
| GLTO | Damora Therapeutics, Inc. | 72% | Reciprocal relationship from GLTO graph: Reciprocal relationship from KPTI graph: Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue … |
| ORANY | ORANY | 72% | respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and prec… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from KPTI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from KPTI graph: respond to the product candidate … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANTENGENE-THERAPEUTICS-LIMITED | ANTENGENE-THERAPEUTICS-LIMITED | 90% | In prior periods, we entered into license agreements with Berlin-Chemie AG, an affiliate of the Menarini Group ("Menarini"), and Antengene Therapeutics Limited ("Antengene"), both of which are accoun… |
| BERLIN-CHEMIE-AG | BERLIN-CHEMIE-AG | 90% | In prior periods, we entered into license agreements with Berlin-Chemie AG, an affiliate of the Menarini Group ("Menarini"), and Antengene Therapeutics Limited ("Antengene"), both of which are accoun… |
| PHARMACY-BENEFIT-MANAGERS | PHARMACY-BENEFIT-MANAGERS | 85% | A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose info… |
| KKR | KKR & Co. Inc. | 72% | Reciprocal relationship from KKR graph: Reciprocal relationship from KPTI graph: Reciprocal relationship from KKR graph: Reciprocal relationship from KPTI graph: ternatives to achieve our business ob… |
| KKR | KKR & Co. Inc. | 72% | ternatives to achieve our business objectives. If we are unable to raise sufficient capital or to enter into strategic alternatives on acceptable terms to meet our needs, we may be forced to delay, r… |
| ORANY | ORANY | 72% | respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and prec… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from KPTI graph: respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeut… |
| ANTENGENE-CORPORATION-CO-LTD | ANTENGENE-CORPORATION-CO-LTD | 62% | ecoverability of our inventory each reporting period and write-down any inventory that has become obsolete, that has a cost basis in excess of its estimated realizable value, or that is not expected … |
| CHANGE-MENARINI-GROUP | CHANGE-MENARINI-GROUP | 62% | n 2025. This increase was primarily attributable to an unusually high product return reserve recorded in the prior-year period, which reduced net revenue in that period, as well as lower gross-to-net… |
| HEALTHCARE-ROYALTY-MANAGEMENT-LLC | HEALTHCARE-ROYALTY-MANAGEMENT-LLC | 62% | ternatives to achieve our business objectives. If we are unable to raise sufficient capital or to enter into strategic alternatives on acceptable terms to meet our needs, we may be forced to delay, r… |
| HEALTHCARE-ROYALTY-PARTNERS | HEALTHCARE-ROYALTY-PARTNERS | 62% | ortized cost basis. Any impairment that is not related to a credit loss is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as a provision for … |
| MENARINI-GROUP | MENARINI-GROUP | 62% | nue in effect on a product-by-product, country-by-country basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of sp… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| KPTI-DEBT-10565 | Warrants outstanding: 0.0001 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| KPTI-DEBT-10566 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| KPTI-DEBT | Debt stack $169.3M | 90% | Market cache reports total debt of $169.3M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| KPTI-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 559,619; ownership 3.05%; value $3.1M; as of 2025-12-31. |
| KPTI-OWNER-BRAIDWELL-LP | Braidwell LP | 95% | 13F/ownership overlay lists Braidwell LP ; shares held 303,370; ownership 1.65%; value $1.7M; as of 2025-12-31. |
| KPTI-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C | Adage Capital Partners GP L.L.C. | 95% | 13F/ownership overlay lists Adage Capital Partners GP L.L.C.; shares held 421,322; ownership 2.30%; value $2.3M; as of 2025-12-31. |
| KPTI-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEMENT-INC | T. Rowe Price Investment Management, Inc. | 95% | 13F/ownership overlay lists T. Rowe Price Investment Management, Inc.; shares held 1,491,409; ownership 8.13%; value $8.2M; as of 2025-12-31. |
| KPTI-OWNER-OPALEYE-MANAGEMENT-INC | Opaleye Management Inc. | 95% | 13F/ownership overlay lists Opaleye Management Inc.; shares held 930,000; ownership 5.07%; value $5.1M; as of 2025-12-31. |
| KPTI-OWNER-SOLEUS-CAPITAL-MANAGEMENT-L-P | Soleus Capital Management, L.P. | 95% | 13F/ownership overlay lists Soleus Capital Management, L.P.; shares held 440,000; ownership 2.40%; value $2.4M; as of 2025-12-31. |
| KPTI-OWNER-AFFINITY-ASSET-ADVISORS-LLC | Affinity Asset Advisors, Llc | 95% | 13F/ownership overlay lists Affinity Asset Advisors, Llc; shares held 889,575; ownership 4.85%; value $4.9M; as of 2025-12-31. |
| KPTI-OWNER-DAVIDSON-KEMPNER-CAPITAL-MANAGEMENT-LP | Davidson Kempner Capital Management LP | 95% | 13F/ownership overlay lists Davidson Kempner Capital Management LP; shares held 310,020; ownership 1.69%; value $1.7M; as of 2025-12-31. |
| KPTI-OWNER-EXOME-ASSET-MANAGEMENT-LLC | Exome Asset Management LLC | 95% | 13F/ownership overlay lists Exome Asset Management LLC ; shares held 295,541; ownership 1.61%; value $1.6M; as of 2025-12-31. |
| KPTI-OWNER-IKARIAN-CAPITAL-LLC | Ikarian Capital, LLC | 95% | 13F/ownership overlay lists Ikarian Capital, LLC; shares held 544,554; ownership 2.97%; value $3.0M; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| VSA | VisionSys AI Inc. | 100.00 | 2 | |
| BBIO | BridgeBio Pharma, Inc. | 100.00 | 2 | |
| KREF | KKR Real Estate Finance Trust Inc. | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 2 | |
| EYE | National Vision Holdings, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| KKR | KKR & Co. Inc. | 100.00 | 1 | ['customer'] |
| SNYNF | Sanofi | 100.00 | 2 | |
| GLTO | Damora Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| MRK | Merck & Co., Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| AUMN | Golden Minerals Company | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 |